Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox As a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece
Overview
Overview
Journal
Value Health
Publisher
Elsevier
Specialties
Biomedical Engineering
Pharmacology
Public Health
Pharmacology
Public Health
Date
2016 May 21
PMID
27202252
Citations
1
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Seo M, Cairns J PLoS One. 2018; 13(9):e0204496.
PMID: 30256829 PMC: 6157891. DOI: 10.1371/journal.pone.0204496.